Physitrack PLC – Interim Report: December 2020 – November 2021
LONDON, UK / ACCESSWIRE / January 26, 2022 / Physitrack (STO:PTRK)Financial highlights for the fourth quarter and twelve month period ended 30 November 2021Fourth quarter 2020/21 (September 2021 - November 2021)Revenue of EUR 2.4m (1.0m) for the …
LONDON, UK / ACCESSWIRE / January 26, 2022 / Physitrack (STO:PTRK)
Financial highlights for the fourth quarter and twelve month period ended 30 November 2021
Fourth quarter 2020/21 (September 2021 - November 2021)
- Revenue of EUR 2.4m (1.0m) for the quarter ended 30 November 2021. An increase of EUR 1.4m or 165 per cent compared to the same period last year.
- Proforma revenue growth of 47 per cent for the quarter ended 30 November 2021 compared to the same period last year.
- This growth was achieved in all businesses:
- 47 per cent revenue growth of the existing Physitrack business compared to the same period last year against a strong prior year comparator
- 11 per cent revenue growth of the acquired Physiotools and Mobilus ("Physiotools") businesses on a proforma basis
- 150 per cent revenue growth of the acquired Rehabplus business on a proforma basis;
- 122 per cent revenue growth of the acquired Fysiotest business on a proforma basis;
- 3 month adjusted EBITDA of EUR 0.8m (0.4m) increased by 106 per cent compared to the same period last year;
- Adjusted EBITDA margins of 32 per cent, a decrease from 41 per cent compared to prior year due to lower margins of recently acquired companies;
- Profit after tax of EUR 0.3m (0.1m) for the quarter.
12 Month period ended 30 November 2021 (December 2020 - November 2021)
- Revenue of EUR 7.7m (3.1m) for the year ended 30 November 2021. An increase of EUR 4.6m or 153 per cent against the same period last year;
- Proforma[1] revenue growth of 36 per cent for the year ended 30 November 2021 against the same period last year. This growth was achieved in all businesses:
- 46 per cent revenue growth of the existing Physitrack business compared to the same period last year
- 11 per cent revenue growth of the acquired Physiotools and Mobilus ("Physiotools") businesses on a proforma basis
- 75 per cent revenue growth of the acquired Rehabplus business on a proforma basis
- 122 per cent revenue growth of the acquired Fysiotest business on a proforma basis;
- 12 month adjusted EBITDA[2] of EUR 2.6m (1.6m), increased by 58 per cent compared to the same period last year;
- Adjusted EBITDA margins[3] of 33 per cent, a decrease from 53 per cent compared to prior year due to previously communicated lower margins of recently acquired companies;
- One-off IPO and M&A expenses were incurred of EUR 1.6m, resulting in a loss after tax of EUR 0.6m (0.6m profit) for the 12 months.
Lesen Sie auch
Henrik Molin, Co-founder and CEO of Physitrack PLC commented:
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte